The list of potential “dementia autoantibodies” is continuously growing and further contains autoantibodies against GFAP (11, 12), alpha1-adrenergic receptors (13), NMDA receptors (14–17), and multiple neuronal antigens in cancer patients with cognitive impairment (18). The gene discussed is GFAP; the disease is dementia.